Fighting Heart Disease with AI
Heart disease is the leading cause of death worldwide, yet today there is no effective way to detect it in frontline healthcare. Most people find out they have it when it’s too late via chest pain, a heart attack or even death. We’re working to revolutionize cardiac diagnostics by enabling more accurate, early detection of heart disease with cutting-edge AI technology. Become a shareholder as we drive the future of heart healthcare in a $30B market opportunity.
Investment Highlights
Game-Changing AI Tech
The first-of-its-kind AI-ECG technology with the potential to save lives on a global scale.
$30B Market Opportunity
With 43 patents protecting our innovation, we’re positioned as a leader in the AI-ECG space.
43 Patents
Our innovation is protected across the U.S. and internationally
No Effective Test to Screen for Heart Disease
Most heart disease can only be detected in cardiology using gold standard specialist imaging equipment and scanners which is far too expensive for screening most people. The electrocardiogram (ECG or EKG) is a straightforward test used extensively in the healthcare industry but it can’t detect most types of heart disease. Conventional ECGs are decades-old technology and generally only detect rhythm-related issues, like arrhythmia or AFib. By then a patient often has late stage heart disease. Earlier, effective heart disease detection would save countless lives.
Few test can be administered in clinic
Payors resist expensive tests for asymptomatic patients
Echocardiogram
Nuclear Stress Test
CT Angiogram
Invasive Angiogram
AI-Powered ECG for Earlier Detection
We’re the only company building next-gen ECG device hardware, cloud-native software, and AI-ECG algorithms to deliver AI-ECG solutions across a wide range of healthcare settings, from large hospital systems to simple nurse-led mobile testing services.
Our MyoVista Insights™ Cloud Platform aims to provide cybersecure, modern and user-friendly software allowing multiple AI-ECG algorithms to be run in an AWS cloud-environment using existing ECG hardware.
Our MyoVista® wavECG™ integrates AI directly into a state-of-the-art ECG device to identify and analyze more data from the electrical signal of the heart. It combines AI-ECG and conventional ECG test results into one comprehensive test allowing earlier detection of a far broader range of heart conditions.
AI-ECG provides the catalyst to modernize the ECG industry which is based on decades-old devices and outdated technology - saving lives and reducing healthcare costs for one of the most widely performed medical tests in the world.
Comprehensive AI-ECG Solutions for anyCare Environment:
MyoVista® wavECG™ Device:
One device using embedded AI, one comprehensive test providing both conventional and AI-ECG results. Designed as a simple test to provide immediate results in a next to patient point-of-care environment.
MyoVista Insights™ Cloud Platform:
A cybersecure software solution that provides AI-ECG results using existing ECG devices. Designed for major hospital systems worldwide to plug into their existing IT systems without the need to change out device hardware.
AI-ECG Positioned to Provide a $30B Revolution in Cardiac Diagnostics
The global ECG market is projected to reach $30B by 2034. With over 100 million ECGs performed annually in the U.S. alone and ~1B worldwide, the demand for advanced diagnostic tools like our AI-ECG is accelerating rapidly. We believe that we have a generational opportunity to help modernize the archaic ECGs, which are one of the most widespread medical tests in the world.
Over 100 million ECGs are performed annually in the U.S. alone; ~1B worldwide.
Medicare has already agreed a $128 AI-ECG reimbursement rate which is on top of the ~$60 rate for traditional ECGs.
Potential for more than $10M in additional annual billing from just a single AI-ECG algorithm in a large health system.
We’re Set to Be a Leader in the Fast Emerging AI-ECG Market
Not only have we created the first-ever AI-powered ECG device, but we’ve protected our innovation from competitors with 43 patents. We’re also receiving validation from top names that reinforce the expectation for rapid widespread potential for adoption not only in the USA but in healthcare across the globe:
Icahn School of Medicine at Mount Sinai, New York, a world leading cardiology hospital is our largest shareholder and licensed its AI-ECG IP to HeartSciences
Long standing collaboration with Rutgers Robert Wood Johnson Hospital System, New Jersey
Beta use and key opinion leader engagement in many European countries
MyoVista® wavECG™ recently selected for demonstration at the United Nations General Assembly Digital Health Symposium as a technology to radically transform healthcare.
"Learn how Rutgers' Innovation Center is leveraging our technology to drive clinical advancements and shape the future of cardiac care."
FDA Clearance and Revenue on Our 2025 Agenda
After several years and over $70 million invested during R&D, FDA submissions and approvals are anticipated in the near term. We expect first FDA approval by the end of the year, opening up the entire US market for us. Our plan for 2025 is designed to drive growth, expand market reach, and work to revolutionize cardiovascular diagnostics worldwide.
Phase 1
Cloud-Native ECG Reporting Platform (Completed in 2024)
Create a modern, secure ECG reporting system running on AWS.
Cybersecure, cloud-native architecture to replace outdated, on-premise systems.
Phase 2
AI-ECG Integration and Marketplace (FDA Submission in H2 2025)
Add AI-powered ECG reporting to the platform.
Support for HeartSciences’ proprietary and third-party AI-ECG algorithms via a marketplace model (like an "app store").
Reduce costs and accelerate adoption of AI-ECG solutions across healthcare settings.
Phase 3
Comprehensive ECG Management System (2026 and Beyond)
Launch a fully modern ECG management system addressing global healthcare needs.
Replace legacy ECG IT systems with a flexible, cost-effective, and cybersecure cloud solution.
Potential to expand use cases to include remote care, such as home-based monitoring and telehealth.
in AI-Powered Cardiac Care
Meet the visionary leaders shaping the future of heart disease detection and prevention.
Extensive experience as CEO and Director of public and private companies managing multi-billion-dollar assets and leading innovative ventures.
Serial entrepreneur with a track record of building and selling technology companies.
Certified Public Accountant with over 15 years of experience in financial reporting and compliance.
Over 25 years in engineering and product development for cardiac devices.
Expert in FDA submissions and regulatory affairs for medical devices
FAQs
What kind of shares are you issuing?
The Company is offering, on a “best efforts’ basis, up to 4,285,714 Units, each Unit consisting of one (1) share of Series D Convertible Preferred Stock and one (1) warrant to purchase common stock. The Units will be sold at an offering price of $3.50 per Unit. The warrants are exercisable at a price of $5.00 for one (1) share of Common Stock.
Where can I find the company’s SEC filings?
All of HeartSciences’ regulatory filings, including financial reports, can be found here:
How much are you raising?
The Units will be sold at an offering price of $3.50 per Unit, for a maximum offering amount of $15,000,000.
How will I get a return on my investment?
Investing in startups is risky and there is no guarantee you will get a return on your investment. However, the fact that our common stock is listed on Nasdaq (Nasdaq: HSCS) opens up an opportunity for you to convert your preferred shares into common stock providing an exit in cash (if you choose to sell the common stock) or desire to hold a more liquid asset. If the value of our Company grows, then you have a higher potential of making a profit on your investment.You are investing in a pre-revenue company selling an emerging technology. Success will be measured in progress towards commercialization and growing revenue and profitability.
When will I receive my shares?
Shares will be issued through the transfer agent, Equiniti Trust Company, LLC after the investment funds clear.
Are there higher fees if you invest via credit card vs. ACH?
No, costs are the same, regardless of how you invest.
How Will I (Investor) Make Money?
The Company expects to achieve many milestones in 2025, including FDA clearance which would be expected to see an increase in our share price. We are already listed on Nasdaq so there is the ability to buy and sell our Common Stock. Additionally, the warrants offer the ability to buy further shares at a fixed price.
How Do I Know People Will Buy This Solution?
The FDA has already created a new clinical pathway specifically for AI-ECG, the American Medical Association issued new reimbursement codes and in early 2025 Medicare agreed to start paying for use of AI-ECG. Mayo Clinic is expected to be one of the early adopters and has already used the reimbursement code for AI-ECG tens of thousands of times.
Are There More Opportunities Ahead?
We are at the beginning of what is expected to be a new era for an ECG and its clinical capabilities and we expect many new opportunities. We would expect to bring a portfolio of valuable algorithms into clinical practice and have plans to roll-out further upgrades for both the MyoVista wavECG device and MyoVista Insights cloud-platform. We also have a number of international opportunities and relationships.
Why Didn't A Bigger Company Do This Already?
The big companies tend to focus on maximizing sales of existing products rather than innovation of new ones. Additionally, the data required to develop new algorithms is held by clinical institutions rather than companies and is a barrier to entry and why our clinical collaborations and partnerships in this field are valuable.
How do you plan to use the proceeds from this funding round?
Proceeds from this offering will be used to fund the Company achieving regulatory clearances for its products as well as on-going R&D and clinical activities, sales and marketing and general corporate purposes.
What is the current valuation of the Company?
Based on the $3.50 conversion price the pre-money valuation is $4 million.
Why Should I Invest?
Your support and commitment will help HeartSciences shape the future of heart healthcare and early detection of heart disease.
How long are you expecting the company to operate before needing another round?
If we are able to raise the full amount it is anticipated that this will allow us to get our first products to market. We would expect to need additional capital at that time to market and sell the product.
What is the exit plan for the company?
We are a Nasdaq listed company. Investors can convert their Preferred Stock to Common Stock and are free to trade it at any time. We also anticipate that as we get into sales the Company may well be attractive for acquisition by a larger medical devices company.
What markets are you currently focused on?
We are a medical technology company focused on making the ECG (also known as an EKG) significantly more clinically valuable so that it can detect heart disease earlier. The ECG is one of the most ubiquitous medical tests in the world and performed millions of times a week across healthcare settings including in hospitals, doctor’s offices, other healthcare providers, and retail and screening clinics.
How many investors do you have already?
We are a listed company with over 3,000 holders of our common stock.
Will you be paying out dividends to investors?
We do not intend to pay dividends in the near future.
What is HeartSciences’ core business?
HeartSciences is focussed on making the ECG (also known as an EKG) far more clinically valuable so that so that it can detect heart disease earlier. We are developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting worldwide, either via our MyoVista Insights™ cloud-platform using one of the millions of ECG devices currently in clinical use or via our MyoVista® wavECG™ Device.
Where are your headquarters located?
Southlake, Texas
How many employees does your Company have?
15
When will the Company expand into additional markets and which ones?
In addition to the USA, we already have established clinical relationships in Europe, Australia and India and have distributors appointed in those markets.
Do you plan to expand internationally?
Yes we already have established clinical relationships in Europe, Australia and India and have distributors appointed in those markets. We intend to market our products in those areas regulatory clearances.
Can you share the roadmap for the next 3-4 years and when you expect to become profitable?
Our business model is based on valuable recurring revenues charging a fee for single use supplies, use of algorithms and/or a SaaS subscription which are all at high margin. We expect revenue to start in 2026 and increase substantially as products are adopted and there is an installed user base. Today, more than 100 million ECG tests are performed in the US alone and accordingly, we expect to become profitable much earlier than most medical device companies.
Do you plan on licensing your technology?
Yes, that is one of several potential revenue streams.
How many patents do you have?
43 patents.
What does your path to profitability look like?
- see 24 above
Who are your competitors? What are your advantages against them?
The traditional ECG market is dominated by large medical device manufacturers like GE Healthcare. However, traditional ECGs are decades old technology. AI-ECG is a fast emerging new field with a handful of early stage companies. We have been around longer and have significantly greater experience and relationships in this field than most other companies. We are the only company developing holistic device and cloud-native device agnostic AI-ECG solutions which will enable us to deliver AI-ECG solutions across a wide range of healthcare settings, from large hospital systems to simple nurse-led mobile testing services
Who is the main audience target for your product/service?
The ECG is one of the most ubiquitous medical tests in the world and performed millions of times a week across healthcare settings including in hospitals, doctor’s offices, other healthcare providers, and retail and screening clinics.
Are you looking to partner with other companies?
We are already partnering with several healthcare institutions and overtime see enormous opportunities for partnering with other companies. Either alternative/ telehealth ECG hardware (such as the Apple watch) or the MyoVista Insights platform providing an AI-ECG marketplace to host third party algorithms.
What have been the main challenges in developing your service/product and how have they been mitigated?
The development of AI-ECG algorithms requires access to significant health care data. We have collaborated with many healthcare institutions such in the US, the UK, Denmark and Australia and licenced considerable IP from Mount Sinai, New York which is one of the world’s leading cardiology healthcare institutions.